Triple-Negative Breast Cancer

>

Latest News

The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.
Phase 3 Trial of Trilaciclib in Triple-Negative Breast Cancer Will Continue

February 13th 2024

The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.

Atezolizumab/Chemo Combo Yields Survival Benefit in Metastatic TNBC
Atezolizumab/Chemo Combo Yields Survival Benefit in Metastatic TNBC

December 21st 2023

Data from the phase 2 KEYLYNK-009 study indicate a lower rate of treatment-related adverse effects with pembrolizumab plus olaparib compared with pembrolizumab plus chemotherapy in those with triple-negative breast cancer.
Pembrolizumab Combo Does Not Improve PFS/OS in Advanced/Metastatic TNBC

December 7th 2023

Event-free survival benefits with pembrolizumab plus chemotherapy in the phase 3 KEYNOTE-522 trial appear to be consistent in triple-negative breast cancer across subgroups based on nodal status, tumor size, and PD-L1 status.
Pembrolizumab/Chemo Improves EFS Vs Chemo in High-Risk TNBC

October 20th 2023

Findings suggest that sensitive circulating tumor DNA analysis may be a valuable tool for guiding neoadjuvant treatment decision-making in early-stage triple-negative breast cancer.
Neoadjuvant Chemotherapy Reduces ctDNA Tumor Fraction in TNBC

October 7th 2023

Video Series
Video Interviews
Podcasts

More News